MB-LUYE@EC2609A

CCOE

STARCOIN GROUP

ONEFORCE HLDGS

ROYAL DELUXE

STELUX HOLDINGS

TE HEALTHCARE

ASIAPAC FIN INV

WELIFE TECH

DRINDA

TIMELESS

02186

01530

LUYE PHARMA (2186.HK) has recently seen its stock price continue to decline, temporarily retracing to the previous low point area. The daily death cross signal is clear, and the short-term bearish atmosphere dominates the market. From a technical perspective, major indicators such as MACD and RSI are showing weakness, with the 5-day and 10-day moving averages continuing to decline, and the K-line combination leaning towards bearish, indicating ongoing market selling pressure. 

On the fundamental side, although LUYE PHARMA has launched some new drugs, the industry as a whole has entered a complex phase of stricter policy regulation, price reductions in medical insurance, and high R&D investments, which affects performance improvement in the short term due to various uncertainties. The overall performance of the pharmaceutical sector has seen a recent decline in participation enthusiasm, with major institutions preferring defensive industries or rotating into high-growth areas. 

In terms of sector linkage, the pharmaceutical sector is weak, with noticeable short-term capital outflows. LUYE PHARMA is constrained by the overall atmosphere, facing systemic adjustment pressure brought about by the industry's "collective bearish" sentiment. In the current sensitive range of the retracement phase, both institutions and short-term funds remain highly sensitive, with price fluctuations easily triggering sector resonance. 

For future trends, attention should be paid to whether the support at this low point is effective. If strong support is breached, short-term bearish signals may further strengthen; conversely, if funds provide support and lead to a reversal of indicators, there may be a technical rebound in the short term. Investors should strictly control risks, primarily adopting a wait-and-see approach when the bottom is unclear, and if making tentative layouts, set appropriate stop-loss levels

Technical Forecast

LUYE PHARMA

3SBIO

Early Morning Trend | LUYE PHARMA retraces to the stage low, can sector linkage change the weakness?

159837

520880

159992

159316

510660

520690

513700

Luye Pharma Group has announced a RMB285 million capital injection into its subsidiary, Nanjing Luye, through a structured deal involving Nanjing Xinan and Ningbo Cinda. This investment will leave Luye Pharma with a 70.01% stake in the subsidiary. The deal includes equity option agreements allowing Luye’s affiliate to buy out new investors' stakes. This transaction is classified as a deemed partial disposal under Hong Kong listing rules, highlighting Luye's flexible financing strategy while maintaining control over its Nanjing operations. The current analyst rating for Luye Pharma stock is a Hold with a price target of HK$3.00.

Tip Ranks

E Fund CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Luye Pharma Injects RMB285 Million into Nanjing Unit via Structured Deal

603368

Luye Pharma Group Ltd. has finalized the transfer of a 25% equity stake in its subsidiary, Nanjing Luye, to NJ Xinshi. As of January 19, 2026, Nanjing Luye is now 75% owned by Luye Pharma and 25% by NJ Xinshi. This partnership agreement ensures that Luye Pharma retains control over Nanjing Luye's governance and strategic objectives.

Reuters

GUANGXI LIUYAO GROUP

LUYE PHARMA POFF

Luye Pharma Completes Transfer of 25% Stake in Nanjing Luye to NJ Xinshi

560600

512010

512290

06955

513120

159892

513060

159506

159102

Shandong Boan Biotechnology Co. Ltd. will transfer 11,986,600 H shares to the Issuer on January 27, 2026, as part of a minority stake deal initiated by its controlling shareholder, Luye Pharma Group Ltd. The board expects no material adverse effects on the company's operations from this transaction. This announcement follows a subscription agreement related to Exchangeable Preference Shares.

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

Guotai CSI Bio-medicine ETF

Tianhong CNI BIOMEDICINE ETF

BOAN BIOTECH

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

China Merchants CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Huaan Hang Seng Biotech ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Yinhua CSI Research Sector 100 ETF

Shandong Boan Biotechnology Transfers 11.99 Million H Shares to Complete Minority Stake Deal

Shandong Boan Biotechnology Co. Ltd. announced that its controlling shareholder, Luye Pharma Group Ltd., will transfer 38.5 million H Shares to the Issuer on January 22, 2026. This transfer is part of a subscription agreement related to Exchangeable Preference Shares. The board expects no material adverse effect on the company's operations from this transaction.

Shandong Boan Biotechnology Transfers 38.5 Million H Shares to New Investor

BOAN BIOTECH announced that its controlling shareholder LUYE PHARMA plans to arrange for its wholly-owned subsidiary Shandong Luye Pharma to further transfer 38.5 million H shares in the market on Thursday (22nd) as part of the proposed transfer. In December last year, LUYE PHARMA's wholly-owned subsidiary Luye Geneora issued several exchangeable preferred shares, allowing preferred shareholders to exchange the relevant shares for the existing H shares held by LUYE PHARMA, involving 100.5 million shares

AASTOCKS

BOAN BIOTECH's controlling shareholder plans to further transfer 38.5 million shares

Luye Pharma Group Ltd. has received acceptance from China's National Medical Products Administration for its New Drug Application for Ruoxinlin® (Toludesvenlafaxine Hydrochloride Sustained-Release Tablets) to treat Generalized Anxiety Disorder. This follows the drug's prior approval in November 2022 for Major Depressive Disorder, marking a significant milestone for the company.

China Accepts Luye Pharma's NDA for Ruoxinlin in Generalized Anxiety Disorder

Luye Pharma Group Ltd. has filed an updated list of directors with the Hong Kong Stock Exchange. The board includes Executive Directors Mr. Liu Dian Bo (Executive Chairman and CEO), Mr. Yang Rong Bing (Vice Executive Chairman), Mr. Yuan Hui Xian, and Ms. Zhu Yuan Yuan. Non-Executive Directors are Mr. Song Rui Lin and Mr. Huang Liming. Independent Non-Executive Directors include Mr. Zhang Hua Qiao, Professor Lo Yuk Lam, Mr. Leung Man Kit, Mr. Choy Sze Chung Jojo, and Ms. Xia Lian, with various committee memberships outlined.

Luye Pharma Group Files Director List with HKEX

Luye Pharma Group Ltd. has appointed Ms. Xia Lian, an independent non-executive director, to its Nomination Committee, effective December 31, 2025. The committee now includes Professor Lo Yuk Lam (chairman), Mr. Zhang Hua Qiao, Mr. Choy Sze Chung Jojo, and Ms. Xia Lian.

Luye Pharma Appoints Xia Lian to Nomination Committee

Luye Pharma Group Ltd. has granted Jiangsu Nhwa Hexin Pharmaceutical Marketing Co., Ltd. exclusive rights to commercialize three long-acting injectable antipsychotics in China. The agreement includes a ten-year term and a one-time, non-refundable licensing fee of USD 20 million. Luye Pharma retains product ownership, marketing authorizations, and intellectual property rights, and will handle manufacturing and supply.

Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Antipsychotics in China

Luye Pharma Group Ltd.'s subsidiary, Luye Geneora Holding Limited, issued 1,500,000 exchangeable preference shares to Bluebell Asset Holding Ltd., owned by RRJ Capital. The proceeds will be used for general working capital, including supplier payments, salaries, and administrative expenses. This transaction was disclosed via the Hong Kong Stock Exchange on December 12, 2025.

Luye Pharma Subsidiary Issues Exchangeable Preference Shares to Bluebell Asset Holding

Luye Pharma Says Five New Products Added to China's Drug Reimbursement List

marketscreener